- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03081390
Migraine and CVD Risk in Women
Mechanisms of Increased Cardiovascular Disease Risk in Women With Migraine
The primary goal of this study is to test the effects of a high-fat, high-carbohydrate mixed meal on candidate modulators of cardiovascular disease risk (inflammation, vascular reactivity, sympathetic nervous system tone, and response to pain) in young adult women with migraine compared with healthy young women. This is study enrolling both cases (women with migraine) and controls (women without migraine), with equal numbers of normal weight and obese women in each group. Participants will undergo a telephone screening and a single day in-person study visit.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19004
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (all):
- Female 18-35 years of age, inclusive
- BMI 18.5-24.9 kg/m2, inclusive
- BMI ≥30 kg/m2
Inclusion Criteria (cases only):
- Diagnosis of migraine per ICHD-3-beta (1-10 migraine days per month)
Exclusion Criteria (all):
- Smoking (current or former)
- Chronic use of medications, including oral contraceptives
- Major medical or psychiatry illness (e.g. diabetes, fibromyalgia, major depression/anxiety)
- Pregnant or nursing
- Allergies or sensitivity to any of the ingredients of the meal
- Inability to fast for 10 hours and/or abstain from caffeine intake for 24 hours
- Treatment with antibiotics or steroids within the previous 3 months
- Treatment with NSAIDs within the previous 1 week
Exclusion Criteria (controls only):
- Migraine headaches, or headaches other than tension-type headaches with a frequency of 1 or fewer days per month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: No migraine, normal weight
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
|
Experimental: No migraine, obese
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
|
Experimental: Migraine, normal weight
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
|
Experimental: Migraine, obese
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
LPS area under the curve (AUC)
Time Frame: LPS is measured at baseline every 30 minutes for 4 hours.
|
The primary study endpoint is lipopolysaccharide (LPS) area under the curve (AUC) during MMTT. |
LPS is measured at baseline every 30 minutes for 4 hours.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Flow-mediated dilation (FMD)
Time Frame: FMD is measured at baseline and 2.5 hours after MMTT.
|
Vascular reactivity via brachial artery ultrasound, expressed as flow-mediated dilation (% of baseline diameter, normalized). |
FMD is measured at baseline and 2.5 hours after MMTT.
|
|
Sympathetic tone at rest and with painful stimulus
Time Frame: Sympathetic tone at rest and with painful stimulus are measured at baseline and 3 hours after MMTT.
|
Sympathetic tone via skin conductance is expressed as mean skin conductance level (SCL) in microsiemens, and assessed at rest and following a pain stimulus (cold pressor test). |
Sympathetic tone at rest and with painful stimulus are measured at baseline and 3 hours after MMTT.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shana E McCormack, MD, Children's Hospital of Philadelphia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 826251
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
After the primary publication is complete, interested investigators can request these data without identifiers. The study team will evaluate the request for scientific rigor and ensure consistency with our protocol, and then provide data without identifiers via secure file-share. This will include the subset of participants who indicated their data could be used for ancillary and/or future studies.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.